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A B S T R A C T   
Porous silicon (PSi) is a biocompatible and biodegradable material, which can be utilized in biomedical appli-
cations. It has several favorable properties, which makes it an excellent material for building engineered 
nanosystems for drug delivery and diagnostic purposes. One significant hurdle for commercial applications of PSi 
is the lack of industrial scale production of nanosized PSi particles. Here, we report a novel two-step production 
method for PSi nanoparticles. The method is based on centrifuge chemical vapor deposition (cCVD) of elemental 
silicon in an industrial scale reactor followed by electrochemical post-processing to porous particles. Physical 
properties, biocompatibility and in vivo biodistribution of the cCVD produced nanoparticles were investigated 
and compared to PSi nanoparticles conventionally produced from silicon wafers by pulse electrochemical 
etching. Our results demonstrate that the cCVD production provides PSi nanoparticles with comparable physical 
and biological quality to the conventional method. This method may circumvent several limitations of the 
conventional method such as the requirements for high purity monocrystalline silicon substrates as starting 
material and the material losses during the top-down milling process of the pulse-etched films to porous 
nanoparticles. However, the electroless etching required for the porosification of cCVD-produced nanoparticles 
limited control over the pore size, but is amenable for scaling of the production to industrial requirements.   
1. Introduction 
Porous silicon (PSi) has been investigated as a biocompatible and 
biodegradable material for biomedical applications already for several 
decades [1–5]. A large surface area is one of the distinctive properties of 
all mesoporous materials, however the easily adjustable pore size and 
versatile possibilities for functionalization of the surface distinguish PSi 
from other mesoporous materials [5–8]. These favorable properties of 
PSi have made it an appealing material for pharmaceutical applications 
and it has been intensively investigated especially as a potential 
platform for engineered drug delivery systems and for imaging [9–12]. 
This has led to development of several successful PSi based systems, e.g., 
for in vivo immunogene therapy [13], anti-cancer chemotherapies [14] 
and brachytherapy [15,16]. The majority of these are still in the pre-
clinical development stage, but the brachytherapy agent 32P doped 
OncoSil™ is currently tested in Phase II clinical trials as a combination 
treatment with chemotherapeutics for treating pancreatic cancer 
[17,18]. Due to the recent great progress in development of new PSi 
based drug delivery systems more candidates can be expected to enter 
the clinical trials within the coming years. 
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Although the porous form of silicon (Si) has been known for decades 
already, there are still only limited number of methods for processing 
porous particles from Si in a controlled manner [8]. Especially, the in-
dustrial scale production of PSi particles with controlled size, 
morphology and pore size has been a challenge. All these are critical 
parameters for pharmaceutical applications. The size, shape, surface 
charge and surface chemistry of nanoparticles influence recognition of 
the particles by the immune system of the body and their subsequent 
removal from the circulation by macrophages [19]. If quickly removed, 
nanocarrier may not reach to the target tissue, e.g., the tumor and it fails 
to carry the drug to its target. The pore size, shape and chemistry of the 
pore wall directly influences drug loading capacity and drug dissolution 
rate of the material [20]. For porosifying of Si, electrochemical etching 
has been the dominating technique until the recently introduced 
methods of metal assisted chemical etching and regenerative electroless 
etching (ReEtching) [21–23]. 
Electrochemical etching has exhibited excellent controllability, but it 
has several drawbacks when large scale production is considered [24]. 
The method requires expensive high purity monocrystalline Si wafers or 
wafer-type starting materials. In addition, the method has proven 
difficult for automation and requires significant amount of manual 
processing. As a top-down method, the production of PSi particles 
consists of several different processing steps, which especially when 
going down into nanoscale increases the material losses and costs of the 
production. Furthermore, the fine-control of morphology of the top- 
down produced particles has proven notoriously challenging. 
Although for microsized PSi particles the fine morphological control has 
been satisfactorily achieved by using photolithographic methods [25], it 
is still elusive for production of nanosized particles in large scale [26]. 
Despite of the intensive research in optimization of the fabrication 
methods for nanosized PSi particles, the current methods have not yet 
reached the demands of industrial scale production in terms of repro-
ducible and narrow size distribution and ecological material consump-
tion. So far, this has been one of the biggest stumbling blocks for 
commercial applications of PSi [27]. 
In this paper, we introduce a simple two-step production process 
enabling large scale production of PSi nanoparticles based on centrifuge 
chemical vapor deposition (cCVD) of elemental Si, followed by elec-
trochemical post-processing to porous particles. Physical properties, 
biocompatibility and in vivo biodistribution of the cCVD produced 
nanoparticles were investigated and compared to PSi nanoparticles 
produced from Si wafers by electrochemical etching. 
2. Materials and methods 
2.1. Materials 
PSi particles were fabricated by using a Dynatec reactor (Dynatec 
Engineering AS, Norway) [28]. Silane was purchased from Praxair 
Norway AS (Oslo, Norway) at 8 N purity. Reagents for PSi etching and 
chemical modification were acquired from various sources, such as V2O5 
(Fisher Scientific Inc.), hydrofluoric acid (HF) 40% and 48%, glacial 
acetic acid (AcOH), n-pentane, 10-undecenoic acid, all from Merck 
KGaA, H2O2 (30%, VWR) and Si wafers (Siegert Wafer GmbH). Amine 
PEG5k acetic acid (5000 Da, ≥95% substitution) was purchased from 
JenKem Technology (Plano, TX, USA). Trypan blue (TB), 1-ethyl-3-(3- 
dimethylaminopropyl)-carbodiimide (EDC), and N-hydrox-
ysuccinimide (NHS) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Dulbecco’s Modified Eagle’s Medium (DMEM) and Roswell Park 
Memorial Institute (RPMI) 1640 were purchased from HyClone™, GE 
Healthcare Lifesciences (Logan, UT, USA) and fetal bovine serum (FBS) 
and Versene solution were purchased from Life Technologies Gibco®, 
USA. CellTiter-Glo® assay was purchased from Promega Corporation, 
USA. Alexa Fluor™ 488 hydrazide, 4′,6-Diamidino-2-phenylindole 
dihydrochloride (DAPI), and CellMask™ DeepRed were purchased from 
Thermo Fisher Scientific (Waltham, MA, USA). Phosphate buffered 
saline (PBS), non-essential amino acids (NEAA), L-glutamine 200 mM, 
penicillin (100 IU mL− 1), streptomycin (100 mg mL− 1) and trypsin 
(2.5%) were purchased from HyClone™, GE Healthcare Lifesciences 
(Logan, UT, USA). Triton X-100 was purchased from Merck Millipore 
(Darmstadt, Germany). All chemicals and solvents for radiolabeling of 
the PSi NPs were obtained from commercial providers and they were 
used without further purification. Ultrapure water (18.2 MΩ⋅cm) was 
prepared on a Milli-Q Integral 10 water purification system. [111In]InCl3 
was purchased from Mallinckrodt Medical B.V. (Petten, The 
Netherlands). 
2.2. Preparation of NPs by centrifuge chemical vapor deposition 
(UnTHCPSi-CVP) 
Silane was loaded into the Dynatec cCVP reactor at 420 ◦C and set 
into rotation at a centripetal acceleration exceeding 1000g. The reactor 
was heated to 650 ◦C initiating the nuclei formation and growth into 
particles. When reaching the desired size, the Si particles were forced to 
the wall, from where they were harvested. The harvested material was 
collected into an inert container and stored under argon until further 
processed. 
The CVP produced Si nanoparticles were initially pre-oxidized under 
ambient air at 500 ◦C before annealing in N2 for 2 h at 900 ◦C. The 
annealed nanoparticles were then porosified by regenerative electroless 
etching [23,29]. The etching was done in a plastic container placed in an 
ice bath, with the etchant continuously magnetically stirred and sparged 
with Ar. The etchant composition was a 1:1 (v/v) ratio of 48% HF and 
AcOH. The primary oxidant V2O5 concentration was 20 mM, with the 
secondary oxidant H2O2 added gradually with a syringe pump over the 
course of the etching. The etching was conducted for 120 min after 
which the PSi nanoparticles (PSi-CVP) were removed from the etchant 
using a pressure filtration flask equipped with a membrane filter with a 
nominal pore size of 200 nm. The filtered particles were washed with 
copious amounts of ethanol (EtOH), aqueous HCl and finally with n- 
pentane after which the etched PSi-CVP NPs were dried in an oven at 65 
◦C for at least 1 h. 
The etched PSi-CVP NPs were then thermally hydrocarbonized under 
a continuous 1:1 (v/v) N2-C2H2 flush for 15 min at room temperature 
(RT) and 15 min at 400 ◦C. Finally, the thermally hydrocarbonized 
(TCH) PSi nanoparticles were cooled back to RT under N2 flush. The NPs 
were then placed into neat 10-undecenoic acid and heated to 120 ◦C for 
16 h. The COOH-terminated UnTHCPSi-CVP nanoparticles were then 
washed from the solution by repeated centrifugation and redispersion 
into EtOH. 
2.3. Preparation of UnTHCPSi NPs by pulsed electrochemical etching 
(UnTHCPSi-PEE) 
Boron doped, p+-type Si(100) wafers of 0.01–0.02 Ω cm resistivity 
were electrochemically anodized in a 1:1 (v/v) 40% HF-EtOH electro-
lyte using an etching profile consisting of alternating low and high 
current density pulses of 50 and 200 mA/cm2. The obtained multilayer 
PSi film was detached from the wafer by increasing the current density 
abruptly to electropolishing region. 
The pulse etched films were then thermally hydrocarbonized under 
1:1 (v/v) N2-C2H2 flush for 15 min at RT followed by 15 min at 500 ◦C, 
and cooled back to RT under N2. The multilayer THCPSi films were 
placed into neat 10-undecenoic acid for 16 h at 120 ◦C. The obtained 
UnTHCPSi films were then wet-ball-milled in Pulverisette 7 Classic 
planetary ball mill (Fritsch GmbH, Germany) using ZrO2 grinding jar 
and 10 mm balls into nanoparticles in 10 vol-% undecenoic acid- 
dodecane milling media, with the final size separation done by centri-
fugation yielding UnTHCPSi-PEE nanoparticles. 
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2.4. Preparation of PEGylated PSi nanoparticles and conjugation with 
Alexa Fluor™ 488 (PEG-CVP, PEG-PEE, Alexa-CVP, Alexa-PEE, Alexa- 
PEG-CVP and Alexa-PEG-PEE) 
UnTHCPSi-CVP or UnTHCPSi-PEE (3 mg) was dispersed in EtOH (1 
mL), and tip-sonicated to have a uniform dispersion. EDC (3 μL, 16.9 
μmol) and NHS (1.2 mg, 10.4 μmol) was added to the dispersion with 
vigorous stirring. The reaction was allowed to stir at room temperature 
for 3 h, which is to activate the carboxylic acid groups. Afterwards, the 
NHS-activated particles were centrifuged at 16110g for 5 min, and 
washed once with ethanol to remove residual EDC/NHS. Finally, the 
particles were redispersed in another 1 mL EtOH containing amine 
PEG5k acetic acid (3 mg, 0.6 μmol). The reaction was allowed to stir for 
3 h, and the particles were centrifuged at 16110g for 5 min, and washed 
3 times with EtOH, water, and EtOH, respectively. The PEG-CVP and 
PEG-PEE were stored as ethanol dispersion at 4 ◦C until further use. 
For fluorescence labelling, UnTHCPSi-CVP or UnTHCPSi-PEE was 
first activated by EDC/NHS reaction, same as described above. Then, 
instead of amine PEG5k acetic acid, 50 μg of Alexa Fluor™ 488 hydrazide 
(0.09 μmol) in 50 μL water was added and the reaction was protected 
from light by foil coverage. The resulted particles (Alexa-CVP and Alexa- 
PEE) were centrifuged at 16110g for 5 min, and washed 3 times with 
EtOH, water, and ethanol, respectively. For the synthesis of Alexa-PEG- 
CVP, UnTHCPSi-CVP was labelled with Alexa Fluor™ 488 hydrazide 
and then PEG5k, to make sure that the fluorescence intensity of Alexa- 
PEG-CVP and Alexa-CVP remained the same. 
2.5. Characterization of the nanoparticles 
The hydrodynamic size (Z-average) and polydispersity index (PdI) of 
the PSi samples were determined using dynamic light scattering (DLS; 
Zetasizer Nano ZS, Malvern Instruments, UK) at RT. The morphology of 
the different nanoparticles was evaluated by transmission electron mi-
croscopy (TEM; Tecnai F12, FEI Company, USA) and field-emission 
scanning electron microscopy (FE-SEM; Apreo S, Thermo Scientific 
Inc., The Netherlands). Fourier Transform infrared (FTIR) spectra were 
recorded on a Bruker Vertex 70 spectrometer using Pike MIRacle 
attenuated total reflectance accessory (Pike Technologies, USA) and a 
Bruker Invenio R spectrometer equipped with a PA301 photoacoustic 
detector (Gasera Oy, Finland). 
The crystalline structure of the samples was studied with X-ray 
diffraction (XRD) measurements using a Panalytical Empyrean diffrac-
tometer in θ/θ Bragg-Brentano geometry with Cu Kα radiation and a 
Fig. 1. Secondary electron micrographs of CVD produced Si NPs (a) as produced, (b) directly annealed at 900 ◦C, (c) oxidized at 500 ◦C prior to annealing at 900 ◦C 
and (d) chemically stabilized into COOH-terminated UnTHCPSi-CVD nanoparticles. 
Fig. 2. X-ray diffractograms of the initial CVD produced PSi NPs (CVD NPs), 
directly annealed nanoparticles and the pre-oxidized, subsequently annealed 
nanoparticles. 
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PIXcel3D detector in scanning line mode. 
The specific surface area (SSA) and pore volume of the samples was 
determined with N2 sorption at − 196 ◦C using TriStar 3000 (Micro-
meritics Inc., USA). The SSA was calculated using the Brunauer-Emmett- 
Teller theory and the pore volume by taking the total adsorbed amount 
at a relative pressure, p/p0 = 0.97 [30]. The average size of the pores 
was estimated by assuming the pores as cylindrical. 
2.6. Cytotoxicity studies 
RAW 264.7 macrophage cells were cultured in high glucose (4.5 g L- 
1) DMEM culture medium, supplemented with 10% FBS, 1% L-gluta-
mine, 1% non-essential amino acids, penicillin (100 IU mL− 1) and 
streptomycin (100 μg mL− 1). MDA-MB-231 and 4T1 breast cancer cells 
were cultured in RPMI 1640 medium supplemented with 10% FBS, 
penicillin (100 IU mL− 1) and streptomycin (100 μg mL− 1). All the cells 
were cultured in the 5% CO2-incubator at 37 ◦C, and 95% relative hu-
midity. The culture media were changed every other day. Prior to each 
test, the cells were passaged using 0.25% (v/v) trypsin EDTA. 
The in vitro cytotoxicity was performed using a CellTiter-Glo® 
luminescent cell viability assay. The cells were seeded overnight on a 96- 
well plate at a density of 1 × 104 cells per well in the cell culture media. 
Afterwards, PSi NPs at different concentrations were added in the plate. 
Triton X-100 solution (1% v/v), and cell culture media without any 
tested materials were used as positive and negative controls, respec-
tively. After 6, 24 and 48 h, the cell viability was detected from the 
luminescent intensity, which represents the amount of ATP produced by 
the viable cells. The assay was carried out using Varioskan™ LUX 
multimode microplate reader (Thermo Fisher Scientific, USA). All 
samples were tested in four replicates. 
2.7. Cell uptake studies 
For TEM imaging, cells were seeded on cover-glass slides at a density 
of 2 × 104 cells per slide. After overnight incubation, UnTHCPSi-PEEs 
and UnTHCPSi-CVPs were added at a concentration of 100 μg mL− 1 
and incubated for 5 h. Cells without particle treatment were used as 
control. Then the particles were removed and cells were washed with 
PBS, before fixation by 4% paraformaldehyde. Then the cells were post- 
fixed with 1% of osmiumtetroxide, dehydrated with graded series of 
Fig. 3. Photoacoustic FTIR absorbance spectra of the (a) initial CVD-produced Si nanoparticles, the pre-oxidized and annealed nanoparticles and the final, modified 
COOH-terminated UnTHCPSi-CVD nanoparticles and of the (b) initial anodized PSi film, after thermal hydrocarbonization (THC) and after chemical modification and 
milling into UnTHCPSi-PEE nanoparticles. 
Fig. 4. Secondary electron micrographs of (a) cross-section and (b) top view with some layers removed from a pulse etched multilayer film prior to milling into 
UnTHCPSi-PEE nanoparticles. 
Table 1 
Average hydrodynamic size, zeta-potential and poly-dispercity index (PdI) of the PSi nanoparticles prepared by CVP and PEE and after different functionalization steps.   
UnTHCPSi-CVP UnTHCPSi-PEE PEG-CVP PEG-PEE 
Z-average (nm in water): 206 ± 2 209 ± 1 210 ± 3 193 ± 4 
PdI 0.18 ± 0.02 0.22 ± 0.02 0.23 ± 0.01 0.17 ± 0.02 
Zeta-potential (mV in water) − 39.1 ± 1.2 − 38.1 ± 0.2 − 31.7 ± 1.3 − 15.5 ± 0.7  
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EtOH (70%, 96%, and 100%), incubated with transitional solvent 
acetone and embedded gradually in Epon. The embedded cells were 
sectioned at a thickness of 80 nm and attached on a copper grid for TEM 
imaging (Tecnai F12, FEI Company, USA). 
For confocal microscopy, cells were seeded on Lab-Tek® chambered 
borosilicate coverglass at a cell density of 1.5 × 104 cells per well in cell 
culture medium. After attachment, the cells were exposed with Alexa 
Fluor™ 488 labelled PSi nanoparticles at 100 μg mL− 1 for 5 h. Then the 
particles were removed and the cells were washed by PBS twice. After 
washing, the cells were fixed by 4% paraformaldehyde at 37 ◦C for 10 
min, and stained by CellMask™ DeepRed, before imaging by a Leica TCS 
SP5 II HCS-A confocal microscope (Leica microsystems, Germany). The 
acquired images were processed by Fiji 1.51 software. 
For flow cytometry analysis, cells were seeded in 48-well plates (5 ×
104 cells per well). After attachment, the cells were exposed with Alexa 
Fluor™ 488 labelled PSi NPs at 100 μg mL− 1. Cells without particle 
treatment were used as control. After 24 h treatment, the particles were 
removed and the cells were washed by PBS twice, before detaching by 
Versene solution. The detached cells were centrifuged at 317g and 
washed with PBS before analysis on BD Accuri™ C6 Flow Cytometer (BD 
Biosciences, USA). After flow cytometry analysis, trypan blue (TB) was 
added to the cell suspension and incubated for 15 min to quench the 
fluorescence on the cell surface. Then the cells were washed by PBS, and 
analyzed again by the flow cytometer. The mean fluorescence intensity 
of each sample (in triplicates) was calculated by BD Accuri™ C6 soft-
ware (BD Biosciences, USA) and normalized with the control. 
2.8. Radiolabelling of the PEG-CVP and PEG-PEE nanoparticles 
PEG-CVP and PEG-PEE particles (1.0 mg in EtOH) were centrifuged 
(10,000 rcf, 5 min) to remove EtOH and redispersed into dimethyl 
formamide (DMF, 0.6 mL) followed by tip sonication (QSonica, New-
town, CT, U.S.A). 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo 
[4,5-b]pyridinium 3-oxide hexafluoro-phosphate (HATU) (2 mg, 5.3 
µmol) in 50 µL DMF, N,N-diisopropylethylamine (DIPEA) (1 µL, 5.7 
µmol) and (E)-cyclonon-4-en-1-yl (3-(2-(2-(2-aminoethoxy)ethoxy) 
ethoxy)propyl)carbamate (TCO-PEG3-NH2) (3 mg, 8.1 µmol) in 3 µL 
DMF were added to the particle solution. The reaction was shaken 
overnight at RT and terminated with centrifugation (10 000 rcf, 5 min) 
to remove the unreacted reagents, and washed once with EtOH and once 
with ultrapure water. TCO-functionalized particles were then redis-
persed back into EtOH for further synthesis. 
DOTA-PEG4-Tz 1 (0.01–0.02 mg, 0.12–0.24 nmol), prepared as 
described previously [31], was mixed in conical centrifuge tube with 
0.2 M ammonium acetate buffer (100–500 µL, pH = 6.8) and [111In] 
InCl3 (2–80 MBq). The mixture was stirred gently for 30 min at 30 ◦C and 
purified by solid phase extraction (Sep-Pak light C-18, Waters Corpo-
ration). The C18 cartridge was pretreated with 2 mL of EtOH and 10 mL 
of ultrapure water. The reaction mixture was loaded to the cartridge, 
washed with 10 mL ultrapure water and the product, [111In]In-DOTA- 
PEG4-Tz ([111In]1), was eluted with 20% EtOH in aqueous solution. The 
TCO functionalized PEG-CVP and PEG-PEE particles, were labeled with 
Fig. 6. The TEM images of (a) UnTHCPSi-PEE, (b) PEG-PEE, (c) UnTHCPSi-CVP, and (d) PEG-CVP.  







Fig. 5. The FTIR spectrum of PEG and UnTHCPSi before and after PEGylation. 
The pink shades highlight the typical bands from PEG. 
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[111In]In-DOTA-PEG4-Tz ([111In]1) for 30 min at 37 ◦C with constant 
shaking and purified by repeated centrifugations twice with EtOH and 
once with water (5 min, 11 900 rcfg). The radiochemical purity of the 
radiolabeled particles was determined with i-TLC-SA (eluent: 50 mmol 
EDTA in 0.9% NaCl) and was >98% for the all particle types. Particle 
size for the radiolabeled particles was measured with Zetasizer Nano ZS 
(Malvern, Worcestershire, U.K.) in PBS solution. 
2.9. Stability of 111In-labeled PEG-CVP and PEG-PEE particles 
The in vitro radiochemical stability of 111In-radiolabeled NPs (PEG- 
CVP and PEG-PEE particles) was investigated in PBS (pH = 7.4) and 50% 
of human plasma in order to confirm that the detected radioactivity 
originates from the radiolabeled particles instead of a free radionuclide. 
All assays were carried out in triplicate. Freshly prepared [111In]In-PEG- 
CVP and [111In]In-PEG-PEE particles (0.3 mg, 2–5 MBq) were added to 
1 mL of PBS and 50% of plasma in a protein LoBind microtube 
(Eppendorf) and incubated at 37 ◦C under constant shaking. At the 
predetermined time points 1 h, 2 h and 5 h the nanoparticles were 
collected by centrifugation and the radioactivity of the pellet and su-
pernatant were separately measured by a dose calibrator (VDC-405, 
Veenstra Instruments). 
2.10. Ex vivo biodistribution studies 
All animal experiments were carried out under a project license 
approved by the National Board of Animal Experimentation in Finland 
(ESAVI/12132/04.10.07/2017) and in compliance with the respective 
institutional, national and EU regulations and guidelines. Mice were 
group-housed in standard polycarbonate cages with aspen bedding and 
with food (Envigo Teklad Global Diet 2916) and tap water available ad 
libitum. Environmental conditions of a 12:12 light/dark cycle, temper-
ature of 22 ± 1 ◦C, and relative humidity of 55 ± 15% were maintained 
throughout the study. 
The ex vivo biodistribution studies were carried out in healthy Balb/c 
female mice purchased from Janvier Laboratories (Saint Berthevin, 
France), aged 8–10 weeks, weighing 18–22 g (total n = 36). [111In]In- 
PEG-CVP and [111In]In-PEG-PEE NPs (100 µg) in 200 µL 0.3% Tween in 
PBS (pH = 7.4), were administered intravenously to the tail vein. The 
mice were sacrificed at the predetermined time points by CO2 asphyxi-
ation followed by cervical dislocation. Tissues were collected at 5, 15, 60 
and 120 min time points for [111In]In-PEG- CVP and [111In]In-PEG-PEE 
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Fig. 7. Cytotoxicity of undecylenic acid (a-c) and PEGylated (d-f) PSi NPs on RAW 264.7, MDA-MB-231 and 4T1 cells for 6, 24, and 48 h.  
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particles at 5 and 60 min time points (n = 4 at each time point). The 
circulation half-life of the particles was determined from venous blood 
samples by collecting a droplet from the tail vein with a needle at 15, 30 
and 45 min after administration for both particles. The collected tissue 
samples were weighted individually, and their radioactivity measured 
by using an automated gamma counter (Perkin Elmer Life Sciences, 
Waltham, MA, USA) 
3. Results and discussion 
3.1. Preparation of PSi nanoparticles by centrifuge chemical vapor 
deposition and by pulsed electrochemical etching 
Chemical vapor deposition (CVD) of Si is based on growth of 
elemental Si to layers through decomposition of monosilane [32] (Eq. 
(1)). It is routinely used for production of thin solid high-purity Si films 
Fig. 8. TEM images of cells after incubation with UnTHCPSi-PEE or UnTHCPSI-CVP, or without particle treatment (control). Red arrows showed the internalized 
particles, and black rectangle areas are enlarged to show the particles. 
Fig. 9. Confocal microscopy images of RAW 267.4 cells after incubation with UnTHCPSi-PEE, PEG-PEE, UnTHCPSi-CVP, PEG-CVP, or without particle treatment 
(control). Green channel shows the particles; red channel represents the cell membrane. Scale bar, 50 µm. 
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for semiconductor industry [33]. For production of PSi nanoparticles, 
SiO2 or Si3N4 substrates are typically needed for initiating the nucleation 
process [34,35]. In this work, PSi nanoparticles were produced in a 
centrifugal chemical vapor deposition reactor (cCVD reactor), in which 
monosilane decomposition at 420 ◦C initializes the chain reaction 
leading to deposition of elemental Si and growth into particles [36]. 
SiH4→Si + 2H2 (1) 
Here, we investigated use of a cCVD reactor for industrial scale 
production of Si nanoparticles, aiming to controllable and narrow par-
ticle size distribution based on separation of the particles with centrif-
ugal forces. The silane was fed into the reactor while the chamber was 
kept heated and the silane was allowed to nucleate to particles in the 
chamber, in which the particles continued to scavenge silane and grow 
[36,37]. Our hypothesis was that as the particles grow, the centripetal 
force would move them towards the wall within their increasing mass, 
while the viscous drag would increase by their cross-section. Since the 
weight scales by r3 and the cross-section by r2, the particles are har-
vested at the same time for each particle as they reach the same r and the 
centripetal force surpasses the viscous drag agglomeration of the parti-
cles during production was observed (Fig. 1a). The primary advantage of 
the applied cCVD method is the capacity coupled with the particle 
specifications. The use of rf-decompositon, laser assisted decomposition 
or plasma assisted decomposition are all based on limiting the growth 
rate by having a low concentration of silane and thus limit the number of 
possible molecular collisions within the growth time [38–40]. Since the 
limiting factor is the available silane, all these methods will have a lower 
production rate and need more energy per decomposed molecule. Our 
cCVD method is operated at atmospheric pressure and above, the growth 
rate is fast and the production rate is high compared to these other 
methods. Laser ablation is another method where silicon particles are 
removed from a silicon bulk surface by means of a high energy laser. The 
method may be effective in producing small particles, but the energy 
needed and the production rate is limited compared to cCVD. 
The process for this particular study utilized a production rate of ca. 
660 g/hour, utilizing a silane flow rate of 10 L/min, with a process yield 
of 97%. The hydrodynamic size of the harvested nanoparticles prior to 
any further processing was according to DLS measurements in EtOH 
approximately 220 ± 1 nm. However, some agglomeration of the par-
ticles during production was observed (Fig. 1a). 
The cCVD reactor produced CVP NPs were amorphous as shown in 
Fig. 2. Prior to the porosification with regenerative etching, the nano-
particles were crystallized by thermally annealing the particles at 900 ◦C 
for 2 h. In order to avoid possible sintering of the particles into larger 
aggregates, a brief low-temperature oxidation in air at 500 ◦C was 
performed prior to the annealing step, preventing further fusion of the 
primary particles, as observed in Fig. 1b. This pre-oxidation step pre-
vented further aggregation of the primary particles, with the appearance 
of the particles after both the annealing and final stabilization remaining 
similar to the initial nanoparticles (Fig. 1c, d). The XRD analysis 
confirmed the successful crystallization of the NPs (Fig. 2). The broad 
amorphous halo from the initial particles is replaced after the annealing 
process with distinct reflections corresponding to polycrystalline Si. 
Also, the pre-oxidation can be seen to have no discernible effect on 
crystallization process. 
The surface chemistry of the particles, however, showed formation of 
an oxide layer, as the initial hydrogen termination after production was 
removed. FTIR measurements done on the initial particles showed a 
clear presence of different Si–Hx and OySi–Hx -groups due to the broad 
band between 2000 and 2250 cm− 1, as shown in Fig. 3. After pre- 
oxidation and annealing, much of the hydrides were removed except 
small indications of back-bond oxidized O3Si–H groups at 2290 cm− 1, 
as well as the presence of silanol groups at 3740 cm− 1. In contrast, a 
broad absorbance band related to Si–O stretching vibrations was 
observed between 1000 and 1200 cm− 1. 
The crystallized particles were then porosified with regenerative 
electroless etching (ReEtching), with reaction conditions adapted for 
gentle etching due to the initial material being already nanoparticles. As 
the etching process is initiated by the VO2+, both the amount of the 



























































Fig. 10. Flow cytometry quantification of cellular uptake. The positive event percentage of RAW 267.4, 4T1 and MDA-MB-231 cells when incubated 24 h with (a) 
Alexa-CVP and Alexa-PEG-CVP and (b) after trypan blue (TB) treatment. 
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The overall amount of added oxidants into the reaction was aimed to 
provide a clearly substoichiometric oxidant to Si ratio of 0.75 with a 
process length of 120 min. 
After ReEtching, the particle structure became porous and N2 sorp-
tion results indicated the material to have an SSA of over 200 m2 g− 1 
with a porosity of ca. 52%. Thermal hydrocarbonization provides 
aqueous stability and a suitable template for subsequent functionaliza-
tion, such carboxylic acid termination through thermal addition of 10- 
undecenoic acid. The initial hydrocarbonization process appeared to 
cause limited structural collapse of the particles, as the functionalized 
UnTHCPSi-CVD nanoparticles indicated slight reduction in porosity to 
47%, but increase in SSA to nearly 280 m2 g− 1. Analysis of the surface 
chemistry of the NPs indicated that the functionalization with COOH- 
groups was successful due to the appearance of a vibration band at 
1715 cm− 1 that can be assigned to carbonyl stretching of the terminal 
acid group (Fig. 3a). 
Anodized PSi nanoparticles with similar surface chemistry were 
fabricated from Si(100) wafers. Structurally, the nanoparticles obtained 
through the pulsed anodization process differ from the CVD-produced 
and subsequently ReEtched nanoparticles through their pore 
Scheme 1. 111In-radiolabeling of the PEG-PEE and PEG-CVP NPs using the click reaction between trans-cyclooctene and [111In]In-DOTA-PEG4-Tz([111In]1).  



























Fig. 11. Radiochemical stability of [111In]In-PEG-CVP and [111In]In-PEG-PEE 
nanoparticles in PBS and 50% human plasma during 5 h. 
D. Lumen et al.                                                                                                                                                                                                                                  
European Journal of Pharmaceutics and Biopharmaceutics 158 (2021) 254–265
263
morphology. While the ReEtch process produces tortuous pores of 4–6 
nm in diameter, the anodization of highly degenerated p+-type wafers 
tends to produce larger pores, with diameters of 10–20 nm as can be 
observed from the micrographs in Fig. 4. After milling into nano-
particles, the SSA and porosity of the nanoparticles were 285 m2 g− 1 and 
64%. However, the final surface chemistry after the addition of the 
COOH-termination is similar to the CVD-produced nanoparticles, as 
shown in Fig. 4b. 
3.2. Surface modification after functionalization with undecylenic acid 
An important aim for surface modification of nanoparticles is to 
improve their biocompatibility and increase in vivo circulation half-life 
and stability. Polyethylene glycol (PEG) is considered as a ‘gold stan-
dard’ for particle/protein surface modification [41] and many PEGy-
lated formulations have been approved by FDA [42]. As a polymer, PEG 
itself is hydrophilic, biocompatible and non-toxic [42]. It has been 
demonstrated to induce a ‘stealth’ effect, which prevents the recognition 
of particles from the immune system. The PEGylation was achieved by 
an EDC/NHS coupling reaction between the undecylenic acid group on 
the UnTHCPSi-CVP and UnTHCPSi-PEE particles and amine group of 
functionalized PEG [43,44]. After the PEGylation, hydrodynamic size 
and PdI of the particles remained almost the same, but the negative zeta- 
potential value decreased, especially for the PEG-PEE (Table 1). FTIR 
confirmed the successful PEGylation since the typical PEG bands (at 
1240 cm− 1, 1340 cm− 1, 1454 cm− 1 and 1466 cm− 1) were visible in both 
PEG-PEE and PEG-CVP (Fig. 5). 
The morphology of PEGylated particles were characterized by TEM 
similarly as the unmodified particles. As shown in Fig. 6, the changes in 
the particle morphology appear to be limited after the PEGylation, 
suggesting conformal polymer coating of the particles. 
3.3. Cytotoxicity studies 
The cytotoxicity of the undecylenic acid modified and PEGylated 
nanoparticles was tested on different mammalian cell lines: RAW 264.7 
(mouse macrophage-like cell line), 4T1 (mouse breast cancer cell line) 
and MDA-MB-231 (human breast cancer cell line, triple negative). As 
shown in Fig. 7, both UnTHCPSi-PEE and UnTHCPSi-CVP showed higher 
than 70% cell viability during all the studied time points on 3 cell lines, 
when the concentration was lower than 0.1 mg mL− 1. At 0.5 and 1 mg 
mL− 1, both particles showed significant decreased viability to different 
extents, especially after the elongation of incubation time to 48 h. Only 
33.7% 4T1 and 40.1% RAW 264.7 cells survived after exposure to 
UnTHCPSi-CVP at 1 mg mL− 1 for 48 h, while 50.3% 4T1 and 57.2% 
RAW 264.7 cells survived with 1 mg mL− 1 UnTHCPSi-PEE after 48 h. 
The decreased cell viability, quantified by ATP present in living cells 
using CellTiter-Glo Assay, showed both UnTHCPSi particles caused ATP 
depletion after exposure to higher concentrations and longer incubation 
time. Compared with the two cancer cell lines, the toxicity effects were 
the highest on RAW 264.7 cells, which was probably due to the massive 
uptake of particles by the macrophages. The higher internalization of 
particles may cause cell apoptosis, because of reactive oxygen species 
production and mitochondrial disruption [45]. 4T1 cells were more 
sensitive to both particles than MDA-MB-231 cells, especially after 48 h- 
incubation. A similar cell-, concentration-, and time-dependent cyto-
toxicity trend was observed on PEGylated particles (PEG-CVP and PEG- 
PEE). Despite the PEGylation, at highest concentrations, 0.5 and 1 mg 
mL− 1, both PEG-CVP and PEG-PEE showed obvious cytotoxicity. PEG- 
CVP was generally more toxic than PEG-PEE at concentrations above 
0.1 mg mL− 1, which was consistent with unmodified UnTHCPSi results. 
3.4. Cell uptake 
The cellular uptake of PSi particles was evaluated on the cell lines 
indicated above, visualized by both TEM and confocal microscopy. TEM 
provides fine details about particle internalization pathway, without any 
labelling. As shown in Fig. 8, RAW 264.7 cells uptake both UnTHCPSi- 
PEE and UnTHCPSi-CVP nanoparticles. In the zoomed images, the 
gird-like structure of UnTHCPSi-PEE and the dense sheet-like structure 
of UnTHCPSi-CVP maintained well after uptake. The particles may have 
been taken-up as aggregates, since more than one particles were iden-
tified in the vesicles. Although similar dark vesicles are shown in the 
control sample without particle treatment, the staining of these vesicles 
was uniform without contrast variations inside. The distinct differences 
between the control and particles treated samples made it clear that the 
particles were internalized in RAW 264.7 macrophages after treatment. 
For 4T1 cells, the uptake was also identified, although the internalized 
particles were less than in RAW 264.7 cells. The internalized particles 
were packed in irregular vesicles or vesicle aggregates, which suggests 
that the particle uptake may rely on endocytosis, and the particles were 
encapsulated in endosome/lysosomes [46,47]. The endosomal/lyso-
somal entrapment was observed on MDA-MB-231 cells alike. 
Confocal microscopy also confirmed the cellular uptake of 
UnTHCPSi particles, after labelling by Alexa Fluor™ 488. As shown in 
Fig. 9, all the particles treated samples showed clear spotty green signals 
in the Alexa channel and dark spots in the bright field channel, sug-
gesting either cell attachment or internalization. Compared with con-
trol, the cell morphology and membrane integrity was well maintained 
after particle treatment, which suggests good biocompatibility. After 
washing, a large amount of UnTHCPSi-CVP were attached to the cell 
membrane more than UnTHCPSi-PEE. After PEGylation, both particles 
showed reduced attachment to cells, confirmed by the fluorescence and 
bright field images. 
Cellular uptake of the non-PEGylated and PEGylated Alexa-CVP and 
Alexa-CVP particles was quantified by flow cytometry. As shown in 
Fig. 10, the number of positive events was the highest in RAW 267.4 
cells for both non-PEGylated particles, while less positive events were 
quantified in MDA-MB-231 cells. Consistent with the confocal images 
shown in Fig. 9, less particle uptake was observed for the PEGylated 
particles in all investigated cell lines. The TB treatment did not cause any 
statistically significant difference in the number of the positive events, 
indicating that the observed signal was contributed by the internalized 
particles rather than those attached on the cell surface (Fig. 10a, b). The 
two investigated breast cancer cell lines (4T1 and MDA-MB-231) 
showed significant difference in the final uptake, in accordance with 
the cell viability results, in which the MDA-MB-231 cells showed the 
highest cell viability after long incubation with the particles (Fig. 7). 
3.5. 111In-radiolabeling and radiochemical stability of NPs in vivo 
PEG-PEE and PEG-CVP NPs were functionalized with trans-cyclo-
octene (TCO) allowing site specific radiolabeling of the particles (RCYs 
= 72 ± 5% and 66 ± 7%, respectively) by using inverse electron demand 
Diels-Alder reaction (IEDDA) between TCO and [111In]In-DOTA-PEG4- 
Tz ([111In]1) (Scheme 1). As reported by us previously, the site specific 
radiolabeling via the IEDDA reaction leads to stable radiolabeling of PSi 
NPs with indium-111 (t1/2 = 2.81 d) and prevents unspecific week co-
ordination of 111In3+ cation to the negatively charged surface of the 
particles. Size of the [111In]In-PEG-CVP and [111In]In-PEG-PEE NPs was 
slightly increased and was 213 ± 3 nm and 268 ± 4 nm, respectively. 
The radiochemical stability of the 111In-radiolabeled NPs was good 
(>89% at 5 h time point) both in PBS and plasma (Fig. 11). 
3.6. Ex vivo biodistribution 
[111In]In-PEG-CVP and [111In]In-PEG-PEE nanoparticles were eval-
uated in mice order to determine possible differences in their bio-
distribution. All mice were injected with 100 µg of labeled particles 
(0.2–0.8 MBq) in 200 µL 0.3% Tween in PBS intravenously into tail vein. 
Blood samples from the contralateral tail vein were taken at the selected 
time points to follow the particle residence time in circulation. Mice 
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were sacrificed and the selected organs were collected for measurement 
of their radioactivity concentration with gamma measurements. Both 
radiolabeled NPs exhibited a typical biodistribution pattern for PSi 
nanoparticles with high uptakes in the liver (69.4 ± 1.4 %ID/g and 71.5 
± 5.0 %ID/g for [111In]In-PEG-PEE and [111In]In-PEG-CVP, respec-
tively) and spleen (81.5 ± 13.6 %ID/g and 60.0 ± 10.7 %ID/g for [111In] 
In-PEG-PEE and [111In]In-PEG-CVP, respectively) at 1 h after intrave-
nous administration (Fig. 12). For [111In]In-PEG-PEE, there was signif-
icantly higher lung uptake (16.9 ± 2.5 %ID/g at 1 h) when compared to 
the [111In]In-PEG-CVP particles (4.5 ± 1.7 %ID/g). The lung accumu-
lation is typical for particles with increasing size, but also surface 
chemistry and shape of nanoparticles may also influence the accumu-
lation [19]. The PEE particles had less negative zeta-potential and 
slightly bigger size, which both may have contributed to the observed 
higher accumulation in lungs. 
Blood radioactivity levels for [111In]In-PEG-CVP and [111In]In-PEG- 
PEE NPs were 12.7 ± 3.4 %ID/g and 7.0 ± 1.1 %ID/g at 5 min after their 
intravenous administration. Despite of the surface PEGylation, the blood 
circulation time of the particles was short and already after 15 min the 
radioactivity levels were dropped to 0.7 ± 0.1 %ID/g and 1.2 ± 0.3 % 
ID/g, respectively (Fig. 13). 
4. Conclusions 
PSi nanoparticles were successfully produced by using the cCVD 
reactor. The produced PSi nanoparticles were amorphous and crystal-
lized by thermally annealing the particles at 900 ◦C prior to the poros-
ification with regenerative etching. Over 50% porosity was achieved, 
but some structural collapse was observed after hydrocarbonization of 
the particles lowering the porosity slightly below 50%. Functionaliza-
tion of the hydrocarbonized nanoparticles with COOH-groups was suc-
cessful, but the subsequent PEGylation did not yield as high PEG 
coverage over the cCVD produced particles as achieved for the PSi 
nanoparticles produced by electrochemical etching. Both particles were 
equally taken-up by the RAW 264.7 cells. The internalized particles were 
packed into irregular vesicles or vesicle aggregates, suggesting that the 
particle uptake may rely on endocytosis, and the particles were encap-
sulated in endosomes and lysosomes. Not surprisingly the highest 
cytotoxicity was observed in RAW 264.7 cells, but only significantly at 
concentrations above 0.1 mg mL− 1. PEGylation decreased macrophage 
uptake for both particle types, but did not have significant influence on 
the observed cytotoxicity of the particles at high concentrations. As 
expected based on the in vitro RAW 264.7 cell uptake, both PEGylated 
nanoparticle types were equally recognized by the immune system in 
vivo and quickly sequestrated from blood by the liver and spleen. Further 
optimization is needed for improving stealth properties of the particles 
with more efficient masking against recognition by the macrophages. 
Overall, the cCVD method provides an alternative method to the 
fabrication of PSi nanoparticles along to the top-down approach utilized 
in the pulsed anodization route. The new route circumvents the limi-
tations placed by the utilization of high purity monocrystalline wafers 
and their subsequent anodization and milling. The electroless etching 
required for the porosification of cCVD-produced nanoparticles limits 
control over the pore size, but allows far greater flexibility in the scaling 
of the production to industrial requirements. However, further optimi-
zation of the cCVD method is needed for minimizing agglomeration of 
the particles in the chamber. This may be achieved by controlling the 
particle growth speed and the surface chemistry of the particles for 
reducing probability of particles to adhere when they collide. 
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Fig. 12. Biodistribution of [111In]In-PEG-CVP and [111In]In-PEG-PEE nano-
particles at 5 min and 1 h after their intravenous administration to Balb/c mice, 
represented as injected dose per gram of solid organ or liquid. Statistical sig-
nificance of the difference (paired t-test) between particles for 5 min time point 
mice: blood p = 0.019, spleen p = 0.0023 and lung p = 0.0054. For the 1 h time 
point mice: spleen p = 0.047 and lung p = 0.00018 (n = 4 for all groups). 
Fig. 13. Radioactivity in blood after intravenous administration of [111In]In- 
PEG-CVP and [111In]In-PEG-PEE particles to Balb/c mice. Blood samples were 
collected from the tail vein at 15 min, 30 min and 45 min after administration 
of the particles (n = 4). The results are indicated as %ID/g in blood. 
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